Reflections from Distant Cuvettes

References

• Shannon J. A. Introductory remarks. Drug Metabolism in Man. Ann. NY Acad. Sci. 1971; Vol. 179: 9–10
   Google Scholar
• Costa E., Karczmar A. G., Vesell E. S. Bernard B. Brodie and the rise of chemical pharmacology. Annu. Rev. Pharmacol. Toxicol 1989; 29: 1–21
   PubMed Web of Science ®Google Scholar
• Brodie B. B., Maickel R. P. Comparative biochemistry of drug metabolism. Proc. Int. Pharmacol. Meeting, 1st Stockholm. Pergamon, Oxford 1961; Vol. 6: 299–324
   Google Scholar
• Quinn G. P., Axelrod J., Brodie B. Species strain and sex differences in metabolism of hexobarbitone, amidopyrine, antipyrine and aniline. Biochem. Pharmacol 1958; 1: 152–159
   Web of Science ®Google Scholar
• Jondorf W. R., Maickel R. P., Brodie B. B. ldquo;Inability of newborn mice and guinea pigs to metabolize drugs”. Biochem. Pharmacol 1958; 1: 352–354
   Web of Science ®Google Scholar
• Vesell E. S. ldquo;On the significance of host factors that affect drug disposition in man”. Clin. Pharmacol. Ther 1982; 31: 1–7
   PubMed Web of Science ®Google Scholar
• Vesell E. S., Beam A. G. ldquo;Localization of lactic acid dehydrogenase activity in serum fractions”. Proc. Soc. Exp. Biol. Med. 1957; 94: 96–99
   PubMed Web of Science ®Google Scholar
• Markert C. L., Moller F. Multiple forms of enzymes: Tissues, ontogenetic, and species specific patterns. Proc. Natl. Acad. Sci. USA 1959; 45: 753–763
   PubMed Web of Science ®Google Scholar
• Axelrod J., Vesell E. S. Heterogeneity of N-O-methyl-transferases. Mol. Pharmacol 1970; 6: 78–84
   PubMedGoogle Scholar
• Ross S., Weinshilboum R. M., Molinoff P. B., Vesell E. S., Axelrod J. ldquo;Electrophoretic properties of dopamine β-hydroxylase in several tissues from three species”. Mol. Pharmacol 1972; 8: 50–58
   PubMed Web of Science ®Google Scholar
• Cohn C. K., Vesell E. S., Axelrod J. ldquo;Studies of a methionine activating enzyme”. Biochem. Pharmacol 1972; 21: 803–809
   PubMed Web of Science ®Google Scholar
• Galton F. ldquo;The history of twins as a criterion of the relative powers of nature and nurture”. J. Br. Anthropol. Inst 1875; 5: 391–406
   Google Scholar
• Bonicke R., Lisboa B. P. Uber die Erbendingtheit der intra-individuellen Konstanz der Isoniazidausscheidung beim Menschen. Naturwissenschaften 1957; 44: 314
   Web of Science ®Google Scholar
• Kalow W. Pharmacogenetics: Heredity and the Response to Drugs. W. B. Saunders, Philadelphia 1962; 231
   Google Scholar
• Vesell E. S. Twin studies in pharmacogenetics. Human Genet 1978; 1(Suppl.)19–30
   Google Scholar
• Nash R. M., Stein L., Penno M. B., Passananti G. T., Vesell E. S. ldquo;Sources of interindividual variations in acetaminophin and antipyrine metabolism”. Clin. Pharmacol. Ther 1984; 36: 417–430
   PubMed Web of Science ®Google Scholar
• Vesell E. S., Page J. G. Genetic control of drug levels in man: Phenylbutazone. Science 1968; 159: 1479–1480
   PubMed Web of Science ®Google Scholar
• Vesell E. S., Page J. G. Genetic control of drug levels in man: Antipyine. Science 1968; 161: 72–73
   PubMed Web of Science ®Google Scholar
• Vesell E. S., Page J. G. ldquo;Genetic control of dicumarol levels in man”. J. Clin. Invest 1968; 47: 2657–2663
   PubMed Web of Science ®Google Scholar
• Vesell E. S., Page J. G., Passananti G. T. ldquo;Genetic and environmental factors affecting ethanol metabolism in man”. Clin. Pharmacol. Ther 1971; 12: 192–201
   PubMed Web of Science ®Google Scholar
• Cascorbi H. F., Vesell E. S., Blake D. A., Helrich M. ldquo;Genetic and environmental influence on halothane metabolism in twins”. Clin. Pharmacol. Ther 1971; 12: 50–55
   PubMed Web of Science ®Google Scholar
• Miller C. A., Slusher L. B., Vesell E. S. ldquo;Polymorphism of theophylline metabolism in man”. J. Clin. Invest 1985; 75: 1415–1425
   PubMed Web of Science ®Google Scholar
• Alexanderson B., Price Evans D. A., Sjoqvist F. ldquo;Steady state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy”. Br. Med. J. 1969; 4: 764–768
   PubMed Web of Science ®Google Scholar
• Andreasen P. B., Froland A., Skovsted L., Andersen S. A., Hauge M. ldquo;Diphenylhydantoin half-life in man and its inhibition by phenylbutazone: The role of genetic factors”. Acta Med. Scand 1973; 193: 561–564
   PubMed Web of Science ®Google Scholar
• Endreny L., Inaba T., Kalow W. ldquo;Genetic study of amobarbital elimination based on its kinetics in twins”. Clin Pharmacol. Ther 1977; 20: 701–714
   Web of Science ®Google Scholar
• Penno M. B., Vesell E. S. ldquo;Monogenetic control of variations in antipyrine metabolite formation: New polymorphism of hepatic drug oxidation”. J. Clin. Invest 1983; 71: 1698–1709
   PubMed Web of Science ®Google Scholar
• Vesell E. S. ldquo;The antipyrine test in clinical pharmacology: Conceptions and misconceptions”. Clin. Pharmacol. Ther 1979; 26: 275–286
   PubMed Web of Science ®Google Scholar
• Danhof M., de Groot-van der Vis E., Breimer D. D. Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high performance liquid chromatography and some preliminary results in man. Pharmacology 1979; 18: 210–223
   PubMed Web of Science ®Google Scholar
• Danhof M., Teunissen M. W. E., Breimer D. D. ldquo;3-Hydroxy-methyl antipyrine excretion in urine after an oral dose of antipyrine”. Pharmacology 1982; 24: 181–184
   PubMed Web of Science ®Google Scholar
• Slusher L. B., Vesell E. S. ldquo;Cimetidine-induced reduction in gastrointestinal absorption of antipyrine and rate constants for formation of its metabolites”. Clin. Pharmacol. Ther 1984; 35: 568–575
   PubMed Web of Science ®Google Scholar
• Welch R. M., DeAngelis R. L., Wingfield M., Farmer T. W. ldquo;Elimination of antipyrine from saliva as a measure of metabolism in man”. Clin. Pharmacol. Ther 1975; 18: 249–258
   PubMed Web of Science ®Google Scholar
• Vesell E. S., Passananti G. T., Glenwright P. A., Dvorchik B. H. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine. Clin. Pharmacol. Ther 1975; 18: 259–272
   PubMed Web of Science ®Google Scholar